Clinical Trials Logo

Healthy Subjects clinical trials

View clinical trials related to Healthy Subjects.

Filter by:

NCT ID: NCT02903095 Completed - Healthy Subjects Clinical Trials

Single Ascending Dose Study of TD-1439 in Healthy Subjects

Start date: September 2016
Phase: Phase 1
Study type: Interventional

Single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-1439 in healthy subjects

NCT ID: NCT02890147 Completed - Healthy Subjects Clinical Trials

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Case-control

PRECISESADST
Start date: December 2014
Phase:
Study type: Observational

Connective tissue diseases (CTD) or systemic autoimmune diseases (SADs) as they are known today are a group of chronic inflammatory conditions with autoimmune aetiology with few treatment options and difficult diagnosis.Brest team contribute to perform a new classification of the following systemic autoimmune diseases in a European Union's Seventh Framework Programme. The aim of this research is to constitute a Healthy Volunteers cohort to compare with systemic autoimmune diseases cohort into molecular clusters instead of clinical entities through the determination of molecular profiles using several "Omics" techniques.

NCT ID: NCT02887053 Completed - Healthy Subjects Clinical Trials

Methodological Developments for Magnetic Resonance Imaging (MRI)

METHODO
Start date: November 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to optimize clinical MR protocols and to validate MR acquisition parameters.

NCT ID: NCT02882425 Completed - Healthy Subjects Clinical Trials

Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Subjects

Start date: January 2015
Phase: Phase 1
Study type: Interventional

The primary purpose of this phase 1 study is to investigate the absolute bio-availability of a single oral dose of selexipag, i.e., to assess the amount of selexipag which reaches the blood when administered as an oral tablet (ACT-293987) compared to an intravenous administration in healthy subjects.

NCT ID: NCT02873156 Completed - Healthy Subjects Clinical Trials

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects

Start date: August 10, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of multiple ascending oral doses of E2027 in healthy participants.

NCT ID: NCT02871687 Completed - Healthy Subjects Clinical Trials

Effect of Statin Use on Aldosterone Secretion

Start date: April 2016
Phase: Phase 1
Study type: Interventional

The purpose of this research protocol is to determine if the same effects are observed in vivo in humans through a randomized controlled study. Data regarding a novel mechanism of the widely used statin class of medications on the mineralocorticoid pathway would likely have significant clinical implications on the future management of hypertension and other cardiovascular disease given the known pleiotropy of aldosterone action.

NCT ID: NCT02847416 Completed - Healthy Subjects Clinical Trials

A Study of Pressure and Flow Characteristics During Inspiration and Expiration Using BreatheMAX® in Healthy Subjects

PFBM
Start date: August 2016
Phase: N/A
Study type: Interventional

the aim of this study are to explore the characteristics of mean airway pressure, oscillatory amplitude and power spectral density (PSD) of oscillatory airway pressure that generate by various loaded and flow rate during expiration and inspiration in healthy subjects and to explore the best loaded and flow rate for airway secretion clearance using the BreatheMAX® device

NCT ID: NCT02844179 Completed - Healthy Subjects Clinical Trials

(+)-Alpha-Dihydrotetrabenazine Phase I

Start date: July 2016
Phase: Phase 1
Study type: Interventional

This research study is intended to determine the initial safety and tolerability of single oral doses of the drug (+)-alpha-dihydrotetrabenaxine (HTBZ) in normal volunteers. HTBZ is believed to be the active ingredient in the FDA-approved drug tetrabenazine (TBZ, brand name Xenazine), prescribed for treatment of involuntary movements in patients with Huntington's chorea. TBZ is a mixture of closely-related compounds (isomers) and is readily metabolized (converted) in the human body to HTBZ and related isomers. Investigators believe that HTBZ, the drug to be studied in this research, is the active ingredient in TBZ. The present study will confirm safety and tolerability of HTBZ and will investigate its expected effects on brain sites that are the target of TBZ therapy.

NCT ID: NCT02841761 Completed - Healthy Subjects Clinical Trials

A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects

Start date: July 1, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effect of ACT-132577 on the pharmacokinetics of midazolam and 1-hydroxy midazolam and to evaluate the safety and tolerability of ACT-132577 when administered alone and in combination with midazolam.

NCT ID: NCT02825537 Completed - Healthy Subjects Clinical Trials

Study of the Effect of Elastic Compression (French Class III) on Water Balance Change in Healthy Subjects

Start date: July 2016
Phase: N/A
Study type: Interventional

The main objective of this study is to compare precisely, under standardized test conditions, water balance changes in healthy subjects with or without the daytime use of compression stocking.